Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: Early results in high risk patients

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 3, 2002, Pages 219-225

  Coblentz, T R ^a   Bissonette, E A ^a   Williams, K R ^a   Theodorescu, D ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Androgen antagnists; Brachytherapy radiotherapy; Prostate neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; LEUPRORELIN; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK;

EID: 0036390731     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500585     Document Type: Article

References (25)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802-1807.
3. Zelefsky MJ et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999; 17: 517-522.
4. Critz FA et al. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol 2000; 164: 738-741.
5. Koppie TM et al. The efficacy of cryosurgical ablation of prostate cancer: The University of California, San Francisco experience. Urol 1999; 162: 427-432.
6. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Ural 1998; 160: 2428-2432.
7. Gerber GS et al. Results of radical prostatectomy in men with clinically localized prostate cancer [see comments]. JAMA 1996; 276: 615-619.
8. Cheng WS et al. Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome: Urology 1993; 42: 283-291.
9. Fair WR, Betancourt JE. Update on memorial sloan-kettering cancer center studies of neoadjuvant hormonal therapy for prostate cancer [In Process Citation]. Mol Urol 2000; 4: 241-248.
10. Laverdiere J et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer [see comments]. Int J Radiat Oncol Riol Phys 1997; 37: 247-252.
11. Pilepich MV et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013-1021.
12. Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comments]. N Engl J Med 1997; 337: 295-300.
13. D'Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [see comments]: JAMA 1998; 280: 969-974.
14. Consensus statement: guidelines for PSA following radiation therapy. American Society for therapeutic Radiology and Oncology Consensus Panel [see comments]. Int J Radiat Oncol Biol Phys 1997; 37: 1035-1041.
15. Partin AW et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [see comments] [published erratum appears in JAMA 1997; 278: 118]: JAMA 1997; 277: 1445-1451.
16. Ling CC. Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992; 23: 81-87.
17. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors (5th edn). John Wiley & Sons: New York, 1992.
18. Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer: Urology 2000; 55: 736-742.
19. Sylvester J, Blasko JC, Grimm P, Ragde H, Interstitial implantation techniques in prostate cancer. J Surg Oncol 1997; 66: 65-75.
20. Critz FA et al. Post-treatment PSA < or=0.2 ng/ml defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 1999; 54: 968-971.
21. Cavanagh W, Blasko JC, Grimm PD, Sylvester JE, Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 2000; 18: 160-165.
22. Critz FA et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000; 163: 1085-1089.
23. Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS, Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12y of observed follow-up. Cancer 2000; 89: 135-141.
24. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000; 18: 1187-1192.
25. Cha CM et al. Isotope selection for patients undergoing prostate brachytherapy [see comments]. Int J Radiat Oncol Biol Phys 1999; 45: 391-395.